Longitude Capital Partners V, LLC
Known title: 10% OwnerCIK: 0002018312
Longitude Capital Partners V, LLC's purchase track record
Longitude Capital Partners V, LLC has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/5/2026 | MANE | $18.27M | +190.2% | +192.4% | +13.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MANE | ▼ Sell | Other | 1,171,121 | — | 2/5/2026 | View on chart |
| MANE | ▼ Sell | Other | 1,236,631 | — | 2/5/2026 | View on chart |
| MANE | ▼ Sell | Other | 1,171,121 | — | 2/5/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 192,647 | $3.3M | 2/5/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 882,353 | $15.0M | 2/5/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Veradermics Momentum Builds, But H2 2026 Readouts Caution
Veradermics has seen growing momentum, but analysts caution that upcoming H2 2026 readouts could influence the stock. The company was included among 12 healthcare stocks that moved higher in Thursday’s intraday session. While the news highlights positive sentiment, investors should note the caution about future readouts. The stock remains near its 52‑week low, with a support level at $97.79.
Veradermics Momentum Builds, But H2 2026 Readouts Caution. Veradermics has seen growing momentum, but analysts caution that upcoming H2 2026 readouts could influence the stock. The company was included among 12 healthcare stocks that moved higher in Thursday’s intraday session. While the news highlights positive sentiment, investors should note the caution about future readouts. The stock remains near its 52‑week low, with a support level at $97.79.